AstraZeneca Taps Regulus For microRNA Drug Development

Alnylam/Isis spinout Regulus nabs two high-profile partners for its microRNA platform by signing an agreement with AstraZeneca that includes a $28 million upfront payment and equity investment, and a separate deal with Biogen Idec.